Sézary Syndrome, T-Helper 2 Cytokines and Accessory Factor-1 (AF-1)

References

• Dummer R., Michie S., Kell D., Gould J., Haeffner A., Smoller B., Warnke R., Wood G. Expression of BCL‐2 protein and Ki‐67 nuclear proliferation antigen in benign and malignant cutaneous T‐cell infiltrates. J Cut Pathol 1995; 22: 11–17
   PubMed Web of Science ®Google Scholar
• Burg G., Braun‐Falco O. Cutaneous lymphomas, pseudolymphomas and related disorders. Springer‐Verlag, Berlin Heidelberg New York Tokyo 1983
   Google Scholar
• Burg G., Dummer R., Kerl H. Classification of cutaneous lymphomas. Derm Clinics 1994; 12: 213–217
   PubMed Web of Science ®Google Scholar
• Sterry W., Mielke V. CD4+ cutaneous T‐cell lymphomas show the phenotype of helper/inducer T‐cells (CD45RA‐ CDw29+). J Invest Dermatol 1989; 93: 413–416
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., Banks P., Chan J., Cleary M., Delsol G., deWolf‐Peeters C., Falini B., Gatter K., Grogan K., Isaacson P., Knowles D., Mason D., Miiller‐Hermelink H. ‐K., Piled S., Piris M., Ralfkiaer E., Warnke R. A revised European‐American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Willemze R., van Vloten W. A., Hermans J., Damsteeg M. J., Meijer C. J. Diagnostic criteria in Sezary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. J Invest Dermatol 1983; 81: 392–397
   PubMed Web of Science ®Google Scholar
• Rappaport H., Thomas L. B. Mycosis fungiodes: the pathology of extracutaneous involvement. Cancer 1974; 34: 1198–1229
   PubMed Web of Science ®Google Scholar
• Wood G. S. Benign and malignant cutaneous lympho‐proliferative disorders including Mycosis fungoides. Neoplastic hematology, D. M. Knowles. Williams & Wilkins, Baltimore 1992; 917–952
   Google Scholar
• Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L. Two types of murine helper T‐cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348–2357
   PubMed Web of Science ®Google Scholar
• Mosmann T. R., Moore K. W. The role of IL‐10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991; 12: A49–A53
   PubMedGoogle Scholar
• Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991; 12: 256–257
   PubMedGoogle Scholar
• Mosmann T. R., Sad S. The expanding universe of T‐cell subsets‐TH1, TH2 and more. Immunology Today 1996; 17: 138–146
   PubMedGoogle Scholar
• Nickoloff B. J., Griffiths C. E. M., Baadsgaard O., Voorhees J. J., Hanson C. A., Cooper K. D. Markedly diminished epidermal keratinocyte expression of intercellular adhesion molecule‐1 (ICAM‐1) in Sezary Syndrome. JAMA 1989; 261: 2217–2221
   PubMed Web of Science ®Google Scholar
• Vowels B., Cassin M., Vonderheid E., Rook A. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. Invest Dermatol 1992; 99: 90–94
   PubMed Web of Science ®Google Scholar
• Dummer R., Kohl O., Gillisson J., Kagi M., Burg G. Peripheral blood mononuclear cells in non‐leukemic cutaneous T‐cell lymphoma patients: reduced proliferation and preferential secretion of a T‐helper 2 like cytokine pattern on stimulation. Arch Dermatol 1993; 129: 433–436
   PubMed Web of Science ®Google Scholar
• Saed G., Fivenson D. P., Naidu Y., Nickoloff B. J. Mycosis fungoides exhibits a Thl‐type cell‐mediated cytokine profile whereas Sezary syndrome expresses a Th2‐type profile. J Invest Dermatol 1994; 103: 29–33
   PubMed Web of Science ®Google Scholar
• Vowels B. R., Lessin S. R., Cassin M., Jaworsky C., Benoit B., Wolfe J. T., Rook A. H. Th2 cytokine mRNA expression in skin in cutaneous T‐cell lymphoma. J Invest Dermatol 1994; 103: 669–673
   PubMed Web of Science ®Google Scholar
• Asadullah K., Döcke W. ‐D., Haeussler A., Sterry W., Volk H. ‐D. Progression of Mycosis fungoides is associated with increasing cutaneous expression of interleukin‐10 (IL‐10) mRNA. J Invest Dermatol 1996; 107: 833–837
   PubMed Web of Science ®Google Scholar
• Saed G., Fivenson D., Nickoloff B. Th2 cytokine profile in cutaneous T‐cell lymphoma‐ Reply. J Invest Derm 1995; 105: 856
   PubMed Web of Science ®Google Scholar
• Lessin S., Vowels B., Rook A. Th2 cytokine profile in cutaneous T‐cell lymphoma. J Invest Derm 1995; 105: 855
   PubMed Web of Science ®Google Scholar
• Wood G. S., Haeffner A. C., Dummer R., Crooks C. Molecular biology techniques for the diagnosis of CTCL. Derm Clinics 1994; 12: 231–241
   PubMed Web of Science ®Google Scholar
• Dunn D. A., Gadenne A. S., Simha S., Lerner E. A., Bigby M., Bleicher P. A. T‐cell receptor V beta expression in normal human skin. Proc Natl Acad Sci USA 1993; 90: 1267–1271
   PubMed Web of Science ®Google Scholar
• Gilks C. B., Ho V. C., Gascoyne R. D., Ellison D. J. T‐cell receptor variable region gene expression in cutaneous T‐cell lymphomas. J Cutan Pathol 1992; 19: 21–26
   PubMed Web of Science ®Google Scholar
• O'Grady J., Krajewski A. S., Ramage E. F. Demonstration of clonality in T‐cell lymphoma using an anti‐T‐cell receptor variable region antibody panel. Histo‐pathology 1990; 17: 553–556
   Google Scholar
• Potoczna N., Boencke W. ‐H., Nestle F. O., Küenzlen C., Sterry W., Burg G., Dummer R. T‐cell receptor beta variable region usage in cutaneous T‐cell lymphomas in comparison to normal and eczematous skin. J Cut Pathol 1996; 23: 298–305
   PubMed Web of Science ®Google Scholar
• Vonderheid E. C., Bigler R. D., Greenberg A. S., Neukum S. J., Micaily B. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response. Am J Clin Oncol 1994; 17: 255–263
   PubMed Web of Science ®Google Scholar
• Dummer R., Heald P. W., Nestle F. O., Ludwig E., Laine E., Hemmi S., Burg G. Senary Syndrome's T‐cell clones display T‐helper 2 cytokines and express the accessory factor‐1 (interferon gamma receptor beta chain). Blood 1996; 88: 1383–1389
   PubMed Web of Science ®Google Scholar
• Yagi H., Tokura Y., Furukawa F., Takigawa M. Cd7‐Positive Sezary Syndrome With a Thl Cytokine Profile. J Am Acad Derm 1996; 34: 368–374
   PubMed Web of Science ®Google Scholar
• Peris K., Niedermeyer H., Cerroni L., Radaskiewicz T., Chimenti S., Höfler H. Detection of Epstein‐Barr virus genome in primary cutaneous T and B cell lymphomas and pseudolymphomas. Arch Derm Res 1994; 286: 364–368
   PubMed Web of Science ®Google Scholar
• Hsu D. H., de Waal Malefyt R., Fiorentino D. F., Dang M. N., Vieira P., de Vries J., Spits H., Mosmann T. R., Moore K. W. Expression of interleukin‐10 activity by Epstein‐Barr virus protein BCRF1. Science 1990; 250: 830–832
   PubMed Web of Science ®Google Scholar
• Vieira P., de Waal‐Malefyt R., Dang M. N., Johnson K. E., Kastelein R., Fiorentino D. F., de Vries J. E., Roncarolo M. G., Mosmann T. R., Moore K. W. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein‐Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A 1991; 88: 1172–1176
   PubMed Web of Science ®Google Scholar
• Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992; 98: 279–285
   PubMed Web of Science ®Google Scholar
• de Vries J. E. Immunosuppressive and anti‐inflammatory properties of interleukin 10. Annals of Medicine 1995; 27: 537–541
   PubMed Web of Science ®Google Scholar
• Moore K. W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T. R. Interleukin‐10. Annual Review of Immunology 1993; 11: 165–90, 135, 572–575
   PubMed Web of Science ®Google Scholar
• Dummer R., Laine E., Dobbeling U., Burg G., Nestle F. T‐cell relevant cytokines during extracorporeal photopheresis (ECP) in Sézary syndrome, detetcted by a newly developped PCR‐ELISA technique. J Invest Dermatol 1995; 104: 653, (abstract)
   Web of Science ®Google Scholar
• Soh J., Donnelly R. J., Kotenko S., Mariano T. M., Cook J. R., Wang N., Emanuel S., Schwartz B., Miki T., Pestka S. Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell 1994; 76: 793–802
   PubMed Web of Science ®Google Scholar
• Hemmi S., Bohni R., Stark G., Di Marco F., Aguet M. A novel member of the interferon receptor family complements functionality of the murine interferon gamma receptor in human cells. Cell 1994; 76: 803–810
   PubMed Web of Science ®Google Scholar
• Marsters S. A., Pennica D., Bach E., Schreiber R. D., Ashkenazi A. Interferon gamma signals via a high‐affinity multisubunit receptor complex that contains two types of polypeptide chain. Proc Natl Acad Sci USA 1995; 92: 5401–5405
   PubMed Web of Science ®Google Scholar
• Pernis A., Gupta S., Gollob K. J., Garfein E., Coffman R. L., Schindler C., Rothman P. Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in TH1 cells. Science 1995; 269: 245–247
   PubMed Web of Science ®Google Scholar
• Bach E., Szabo S., Dighe A., Ashkenazi A., Aguet M., Murphy K., Schreiber R. Ligand‐induced autoregulation of IFN‐gamma receptor beta chain expression in T‐helper subsets. Science 1995; 270: 1215–1218
   PubMed Web of Science ®Google Scholar
• Kaye F. J., Bunn P. J., Steinberg S. M., Stocker J. L., Ihde D. C., Fischmann A. B., Glatstein E. J., Schechter G. P., Phelps R. M., Foss F. M., Parlette H., Anderson M., Sausville E. A randomized trial comparing combination electron‐beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784–1790
   PubMed Web of Science ®Google Scholar
• Dummer R., Häffner A. C., Hess M., Burg G. A rational approach to the therapy of cutaneous T‐cell lymphomas. Onkologie 1996; 19: 226–230
   Web of Science ®Google Scholar
• Brunda M. J. Interleukin‐12. J Leukoc Biol 1994; 55: 280–288
   PubMed Web of Science ®Google Scholar
• Rook A. H., Kubin M., Cassin M., Vonderheid E. C., Vowels B. R., Wolfe J. T., Wolf S. F., Singh A., Trinchieri G., Lessin S. R. IL‐12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995; 154: 1491–1498
   PubMed Web of Science ®Google Scholar
• Foss F. M., Borkowski T. A., Gilliom M., Stetler S. M., Jaffe E. S., Figg W. D., Tompkins A., Bastian A., Nylen P., Woodworm T., et al. Chimeric fusion protein toxin DAB486IL‐2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin‐2 receptor expression in a phase II study. Blood 1994; 84: 1765–1774
   PubMed Web of Science ®Google Scholar